According to filings with the U.S. Securities and Exchange Commission, Lyndra Therapeutics is raising $179,262,848.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Patricia Hurter played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lyndra Therapeutics
Welcome to Lyndra Therapeutics: Medicine, reinvented Imagine taking a weeks worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics LYNX drug delivery platform is making that possible. Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication. Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.

To learn more about Lyndra Therapeutics, visit http://lyndra.com/

Contact:
Patricia Hurter, President and Chief Executive Officer
857-304-4512
https://www.linkedin.com/in/patricia-hurter-5b96861/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.